Skip to main content

Impetigo

8
Pipeline Programs
6
Companies
8
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
3
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 10 programs with unclassified modality

Competitive Landscape

6 companies ranked by most advanced pipeline stage

ViiV Healthcare
ViiV HealthcareNC - Durham
3 programs
1
1
RetapamulinPhase 4
SB-275833 ointment, 1%Phase 3
RetapamulinN/A
Leo Pharma
Leo PharmaDenmark - Ballerup
2 programs
1
1
Fucidin® creamPhase 41 trial
TD1414 2% creamPhase 21 trial
Active Trials
NCT00626795Completed773Est. Jun 2009
NCT00986856Terminated58Est. Mar 2005
Ferrer
FerrerSpain - Barcelona
2 programs
2
OzenoxacinPhase 3Small Molecule1 trial
ozenoxacin placeboPhase 31 trial
Active Trials
NCT02090764Completed412Est. May 2015
NCT01397461Completed465Est. Dec 2012
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
1
ATx201Phase 21 trial
Active Trials
NCT03429595Completed210Est. Jun 2018
Vyne Therapeutics
Vyne TherapeuticsIsrael - Ness Ziona
1 program
1
Topical Minocycline Foam FXFM244Phase 21 trial
Active Trials
NCT01171326Completed32Est. Apr 2012
GSK
GSKLONDON, United Kingdom
2 programs
RetapamulinN/A1 trial
RetapamulinPHASE_41 trial
Active Trials
NCT01153828Completed1Est. Aug 2012
NCT01126268Completed38Est. Nov 2012

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
GSKRetapamulin
Leo PharmaFucidin® cream
FerrerOzenoxacin
Ferrerozenoxacin placebo
UNION therapeuticsATx201
Vyne TherapeuticsTopical Minocycline Foam FXFM244
Leo PharmaTD1414 2% cream
GSKRetapamulin

Clinical Trials (8)

Total enrollment: 1,989 patients across 8 trials

NCT01126268GSKRetapamulin

Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection

Start: Apr 2010Est. completion: Nov 201238 patients
Phase 4Completed
NCT00986856Leo PharmaFucidin® cream

Fucidin® Cream in the Treatment of Impetigo

Start: May 2004Est. completion: Mar 200558 patients
Phase 4Terminated
NCT02090764FerrerOzenoxacin

Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo

Start: Jun 2014Est. completion: May 2015412 patients
Phase 3Completed
NCT01397461Ferrerozenoxacin placebo

Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo

Start: Mar 2012Est. completion: Dec 2012465 patients
Phase 3Completed
NCT03429595UNION therapeuticsATx201

Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With Impetigo

Start: Feb 2018Est. completion: Jun 2018210 patients
Phase 2Completed
NCT01171326Vyne TherapeuticsTopical Minocycline Foam FXFM244

Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Impetigo Patients

Start: Aug 2010Est. completion: Apr 201232 patients
Phase 2Completed
NCT00626795Leo PharmaTD1414 2% cream

Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)

Start: Feb 2008Est. completion: Jun 2009773 patients
Phase 2Completed
NCT01153828GSKRetapamulin

EU PV for Retapamulin-Prescribing

Start: Nov 2008Est. completion: Aug 20121 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.